Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)
The progression free survival could be prolonged adding pseudomonas aeruginosa to monotherapy capecitabine.
Metastatic Breast Cancer
DRUG: capecitabine and pseudomonas aeruginosa combination
progression free survival, 1 year
overall response rate, 1 year
the efficacy of the combination is much better than monotherapy